 Theratechnologies Inc NASDAQ: THTX has announced results from a study evaluating an intravenous IV push form of Trogarzo ibalizumab-uiyk for HIV-1 infection. The TMB-302 study was conducted by the Companys partner, TaiMed Biologics, to evaluate the current Trogarzo IV Infusion with a more convenient IV Push form that can be infused within 30 seconds without dilution to the 15-minute infusion time of the original IV Infusion. 